JPMorgan Chase & Co. Has Lowered Expectations for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price decreased by JPMorgan Chase & Co. from $12.00 to $10.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 5.71% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. BMO Capital Markets lowered their price objective on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating for the company in a research report on Thursday, September 17th. Bank of America reissued a “buy” rating on shares of DENTSPLY SIRONA in a research note on Friday. Barrington Research decreased their price target on shares of DENTSPLY SIRONA from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Monday, October 26th. Barclays raised their price target on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a report on Monday, August 24th. Finally, Piper Sandler dropped their price objective on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Friday, October 9th. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.42.

DENTSPLY SIRONA Price Performance

DENTSPLY SIRONA stock opened at $9.46 on Friday. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.04 and a current ratio of 1.63. The firm has a market cap of $1.89 billion, a P/E ratio of -15.26, a P/E/G ratio of 1.27 and a beta of 0.87. The business’s fifty day moving average is $9.60 and its two-hundred day moving average is $11.28. DENTSPLY SIRONA has a 52 week low of $8.14 and a 52 week high of $14.76.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $0.29 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.02). DENTSPLY SIRONA had a positive return on equity of 20.21% and a negative net margin of 3.38%. The business had revenue of $836.00 million for the quarter, compared to the consensus estimate of $861.68 million. During the same quarter in the previous year, the company posted $0.37 EPS. DENTSPLY SIRONA’s revenue for the quarter was down 7.5% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. Equities research analysts forecast that DENTSPLY SIRONA will post 1.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several large investors have recently bought and sold shares of XRAY. Nykredit A S bought a new stake in DENTSPLY SIRONA in the second quarter valued at approximately $38,000. IFP Advisors Inc boosted its position in shares of DENTSPLY SIRONA by 244.4% during the third quarter. IFP Advisors Inc now owns 5,566 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 3,950 shares in the last quarter. Allworth Financial LP bought a new position in DENTSPLY SIRONA during the second quarter worth about $51,000. Public Employees Retirement System of Ohio bought a new position in shares of DENTSPLY SIRONA during the 2nd quarter valued at about $69,000. Finally, Citizens Financial Group Inc. RI acquired a new position in shares of DENTSPLY SIRONA in the second quarter valued at approximately $118,000. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.